AU2001275474A1 - Materials and methods for the control of nematodes - Google Patents

Materials and methods for the control of nematodes

Info

Publication number
AU2001275474A1
AU2001275474A1 AU2001275474A AU7547401A AU2001275474A1 AU 2001275474 A1 AU2001275474 A1 AU 2001275474A1 AU 2001275474 A AU2001275474 A AU 2001275474A AU 7547401 A AU7547401 A AU 7547401A AU 2001275474 A1 AU2001275474 A1 AU 2001275474A1
Authority
AU
Australia
Prior art keywords
nematodes
materials
methods
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275474A
Inventor
Alexy M. Eroshkin
Jerald S. Feitelson
Arcady R. Mushegian
Christopher G Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AKKADIX Corp
Original Assignee
AKKADIX CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AKKADIX CORP filed Critical AKKADIX CORP
Publication of AU2001275474A1 publication Critical patent/AU2001275474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
AU2001275474A 2000-06-12 2001-06-12 Materials and methods for the control of nematodes Abandoned AU2001275474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21091700P 2000-06-12 2000-06-12
US60/210,917 2000-06-12
PCT/US2001/018911 WO2001096584A2 (en) 2000-06-12 2001-06-12 Materials and methods for the control of nematodes

Publications (1)

Publication Number Publication Date
AU2001275474A1 true AU2001275474A1 (en) 2001-12-24

Family

ID=22784842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275474A Abandoned AU2001275474A1 (en) 2000-06-12 2001-06-12 Materials and methods for the control of nematodes

Country Status (2)

Country Link
AU (1) AU2001275474A1 (en)
WO (1) WO2001096584A2 (en)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211711B2 (en) * 1999-03-25 2007-05-01 Arborgen, Llc Compositions and methods for the modification of gene expression
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
ATE519774T1 (en) 2002-02-20 2011-08-15 Sirna Therapeutics Inc RNA DISRUPTION-MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
ES2465574T3 (en) 2002-05-03 2014-06-06 Duke University A method to regulate gene expression
US7803984B2 (en) * 2002-07-10 2010-09-28 Kansas State University Research Foundation Compositions and methods for controlling plant parasitic nematodes
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US8158420B2 (en) 2003-04-04 2012-04-17 The Trustees Of Columbia University In The City Of New York Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
US8217157B2 (en) 2003-05-19 2012-07-10 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
WO2005071091A1 (en) * 2003-12-23 2005-08-04 Bayer Cropscience Sa Method for modifying gene expression of a phytopathogenic fungus
US7622301B2 (en) 2004-02-24 2009-11-24 Basf Plant Science Gmbh Compositions and methods using RNA interference for control of nematodes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CN101437834B (en) 2004-07-19 2012-06-06 贝勒医学院 Modulation of cytokine signaling regulators and applications for immunotherapy
BRPI0514342A2 (en) 2004-08-13 2009-10-06 Basf Plant Science Gmbh double stranded rna molecule, grouping of double stranded rna molecules, transgenic plant, and methods for controlling a parasitic nematode's infection of a plant and for manufacturing a transgenic plant
US20060247197A1 (en) 2004-10-04 2006-11-02 Van De Craen Marc Method for down-regulating gene expression in fungi
WO2006044480A2 (en) 2004-10-13 2006-04-27 University Of Georgia Research Foundation, Inc. Nematode resistant transgenic plants
CN101107362A (en) 2004-10-21 2008-01-16 文甘扎公司 Methods and materials for conferring resistance to pests and pathogens of plants
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
JP5832062B2 (en) 2005-05-31 2015-12-16 デフヘン・ナムローゼ・フェンノートシャップＤＥＶＧＥＮ ｎｖ RNAi for insect and spider control
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
CA2660661A1 (en) 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
BRPI0706266A2 (en) * 2006-01-12 2009-02-25 Devgen Nv Pest control methods using rnai
EP2348115A3 (en) * 2006-01-12 2012-01-18 deVGen N.V. Transgenic plant-based methods for plant pests using RNAi
US20100068172A1 (en) * 2006-03-16 2010-03-18 Devgen N.V. Nematode Control
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP5524610B2 (en) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク Transcobalamin receptor polypeptides, nucleic acids and modulators thereof, and related methods used to regulate cell growth and to treat cancer and cobalamin deficiency
US20100011463A1 (en) 2007-02-06 2010-01-14 Basf Plant Science Gmbh Compositions and Methods Using RNA Interference for Control of Nematodes
WO2008095910A1 (en) 2007-02-08 2008-08-14 Basf Plant Science Gmbh Compositions and methods using rna interference of opr3-like gene for control of nematodes
ATE524553T1 (en) 2007-02-09 2011-09-15 Basf Plant Science Gmbh COMPOSITIONS AND METHODS USING CDPK-LIKE RNA INTERFERENCE TO CONTROL NEMATODES
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
EP2222344A4 (en) 2007-11-30 2012-11-07 Baylor College Medicine Dendritic cell vaccine compositions and uses of same
AR075465A1 (en) 2008-10-22 2011-04-06 Basf Se USE OF SULFONILUREA HERBICIDES IN CULTIVATED PLANTS
WO2010046422A2 (en) 2008-10-22 2010-04-29 Basf Se Use of auxin type herbicides on cultivated plants
US20120084882A1 (en) 2009-03-20 2012-04-05 Basf Plant Science Company Gmbh Nematode-resistant transgenic plants
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
EP2501414B1 (en) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
US20130091598A1 (en) 2010-02-23 2013-04-11 Basf Plant Science Company Gmbh Nematode-Resistant Transgenic Plants
EP2588617B1 (en) 2010-07-01 2015-12-30 E. I. du Pont de Nemours and Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
CN108103085A (en) 2010-12-09 2018-06-01 宾夕法尼亚大学董事会 The purposes of the T cell treating cancer of Chimeric antigen receptor-modification
CN103442768A (en) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 Compositions and methods for treating cancer
AU2012321317B2 (en) 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
ES2888651T3 (en) 2011-07-29 2022-01-05 Univ Pennsylvania costimulatory switching receptors
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
WO2013050410A1 (en) 2011-10-04 2013-04-11 Bayer Intellectual Property Gmbh RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9644179B2 (en) 2011-11-23 2017-05-09 The Trustees Of The University Of Pennsylvania Use of PDL1 expressing cells to convert T cells into regulatory T cells
JP2015513399A (en) 2012-02-22 2015-05-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Compositions and methods for generating surviving populations of T cells useful for the treatment of cancer
EP3747898B1 (en) 2012-02-22 2023-03-15 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
ES2959443T3 (en) 2012-02-22 2024-02-26 Univ Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
EP4148135A1 (en) 2012-07-05 2023-03-15 The Trustees of the University of Pennsylvania U1 snrnp regulates gene expression and modulates oncogenicity
MX370495B (en) 2012-07-13 2019-12-13 Univ Pennsylvania Methods of assessing the suitability of transduced t cells for administration.
EP2872526B1 (en) 2012-07-13 2020-04-01 The Trustees of the University of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
EP2903437A1 (en) 2012-10-01 2015-08-12 Basf Se Use of n-thio-anthranilamide compounds on cultivated plants
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AR093909A1 (en) 2012-12-12 2015-06-24 Bayer Cropscience Ag USE OF ACTIVE INGREDIENTS TO CONTROL NEMATODES IN CULTURES RESISTANT TO NEMATODES
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
CA2901960C (en) 2013-02-20 2022-10-04 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2814962T3 (en) 2013-02-20 2021-03-29 Novartis Ag Efficient targeting of primary human leukemia using anti-CD123 chimeric antigen receptor modified T cells
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
ES2769574T3 (en) 2013-03-15 2020-06-26 Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
SG11201604815RA (en) 2013-12-19 2016-07-28 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101A4 (en) 2013-12-20 2017-12-06 Novartis AG Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
ES2939760T3 (en) 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
CA2940671A1 (en) 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA2984484C (en) 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
RU2747384C2 (en) 2014-07-21 2021-05-04 Новартис Аг Cancer treatment with chimeric cd33 antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
ES2781175T3 (en) 2014-07-31 2020-08-31 Novartis Ag Optimized subset of T cells containing a chimeric antigen receptor
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
TW202140557A (en) 2014-08-19 2021-11-01 瑞士商諾華公司 Treatment of cancer using a cd123 chimeric antigen receptor
EP3967709A1 (en) 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN106973568B (en) 2014-10-08 2021-07-23 诺华股份有限公司 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
US20190054117A1 (en) 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
CN107567461A (en) 2014-12-29 2018-01-09 诺华股份有限公司 The method for preparing Chimeric antigen receptor expression cell
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN115029362A (en) 2015-02-06 2022-09-09 新加坡国立大学 Nucleic acids, engineered immune cells comprising the same, methods of production and uses thereof
US10273280B2 (en) 2015-02-27 2019-04-30 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
MY186708A (en) 2015-04-03 2021-08-11 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
HUE054435T2 (en) 2015-04-06 2021-09-28 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016162371A1 (en) 2015-04-07 2016-10-13 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
MX2017012939A (en) 2015-04-08 2018-05-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell.
JP7114457B2 (en) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286322A1 (en) 2015-04-21 2018-02-28 Novartis AG Rna-guided gene editing system and uses thereof
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
AU2016257721B2 (en) 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016283102B2 (en) 2015-06-25 2021-03-11 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods of use thereof
CN108135938A (en) 2015-07-16 2018-06-08 耶达研究及发展有限公司 Anti- third party's central type memory T cell of genetic modification and its purposes in immunotherapy
CN109476722A (en) 2015-07-21 2019-03-15 诺华股份有限公司 The method of the effect of for improving immunocyte and expansion
EP4218777A3 (en) 2015-08-28 2023-08-23 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108780084B (en) 2015-09-03 2022-07-22 诺华股份有限公司 Biomarkers predictive of cytokine release syndrome
BR112018005741A2 (en) 2015-09-22 2018-10-09 Univ Pennsylvania T-cell redirection method to treat HIV infection
RU2022103665A (en) 2015-10-23 2022-03-05 Еурека Терапьютикс, Инк. CHIMERIC ANTIBODY/T-CELL RECEPTOR CONSTRUCTS AND THEIR APPLICATIONS
US10865396B2 (en) 2015-10-29 2020-12-15 Temple University—Of the Commonwealth System of Higher Education Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta
MX2018005315A (en) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc Compositions and methods for treatment of cancer.
JP2018536434A (en) 2015-10-30 2018-12-13 アレタ・バイオセラピューティクス・インコーポレイテッドＡｌｅｔａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Compositions and methods for tumor transduction
US11400145B2 (en) 2015-11-27 2022-08-02 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
FI3383920T3 (en) 2015-11-30 2024-04-10 The Regents Of The Univ Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP7082055B2 (en) 2015-12-22 2022-06-07 ノバルティス アーゲー Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment
AU2016380262B2 (en) 2015-12-28 2023-02-09 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
US11320422B2 (en) 2016-01-06 2022-05-03 Lonza Ltd. Inhibition of protein degradation for improved production
US11441146B2 (en) 2016-01-11 2022-09-13 Christiana Care Health Services, Inc. Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
EP3426217A1 (en) 2016-03-10 2019-01-16 Lonza Ltd Customizable facility
CN109715207B (en) 2016-03-29 2023-03-31 南加利福尼亚大学 Chimeric antigen receptors for targeting cancer
SG11201808992UA (en) 2016-04-14 2018-11-29 Lonza Ag Compositions and methods for the detection of host cell proteins
KR20220133318A (en) 2016-04-15 2022-10-04 노파르티스 아게 Compositions and methods for selective protein expression
WO2017181101A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric alloantigen receptor t cells
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
JP6959942B2 (en) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited Modulation of lipid metabolism for protein production
KR102530742B1 (en) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2017279548A1 (en) 2016-06-08 2018-12-13 Precigen, Inc. Cd33 specific chimeric antigen receptors
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3031289A1 (en) 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells to treat cancer
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
AU2017306267A1 (en) 2016-08-01 2019-02-14 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR102480770B1 (en) 2016-08-02 2022-12-22 론자 리미티드 Customizable facility
US20190169675A1 (en) 2016-08-12 2019-06-06 Lonza Ltd Proteomic analysis of host cell proteins
US11307205B2 (en) 2016-09-19 2022-04-19 University Of Southern California Non-radioactive cytotoxicity assays
JP6887492B6 (en) 2016-10-04 2021-07-14 プレシジョン バイオサイエンシズ，インク． Co-stimulation domain for use in genetically modified cells
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
KR20190058509A (en) 2016-10-07 2019-05-29 티씨알2 테라퓨틱스 인크. Compositions and methods for T-cell receptor reprogramming using fusion proteins
EP3535396A1 (en) 2016-11-01 2019-09-11 Novartis AG Methods and compositions for enhancing gene editing
CA3043752A1 (en) 2016-11-22 2018-05-31 National University Of Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR102275008B1 (en) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. prostate specific membrane antigen binding protein
JP7215997B2 (en) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． Trispecific proteins targeting prostate specific membrane antigen (PSMA) and methods of use
US20210187022A1 (en) 2016-12-21 2021-06-24 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
AU2018207281A1 (en) 2017-01-10 2019-07-18 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
CA3048501A1 (en) 2017-01-10 2018-07-19 Christiana Care Health Services, Inc. Methods for in vitro site-directed mutagenesis using gene editing technologies
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
EP3571295A1 (en) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
US11597911B2 (en) 2017-02-27 2023-03-07 Life Technologies Corporation Expansion of populations of T cells by the use of modified serum free media
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018191490A1 (en) 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
KR20200012860A (en) 2017-04-26 2020-02-05 유레카 쎄라퓨틱스, 인코포레이티드 Constructs that specifically recognize glypican 3 and uses thereof
IL310182A (en) 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Chimeric antibody/t-cell receptor constructs and uses thereof
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3634493A1 (en) 2017-05-08 2020-04-15 Precision BioSciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3067972A1 (en) 2017-06-16 2018-12-20 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
EP3648789B9 (en) 2017-07-03 2023-09-27 Université de Strasbourg Mtmr2-s polypeptide for use in the treatment of myopathies
CN109456943A (en) 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 Universal Chimeric antigen receptor T cell technology of preparing
JP2020533986A (en) 2017-09-15 2020-11-26 ライフ テクノロジーズ コーポレーション Compositions and methods for culturing and growing cells
AU2018338423A1 (en) 2017-09-20 2020-04-09 Sangamo Therapeutics France Novel anti-HLA-A2 antibodies and uses thereof
CN109554348A (en) 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 It can induce the engineering immunocyte of secretion anti-cd 47 antibody
EP3692057B9 (en) 2017-10-03 2023-10-04 Precision BioSciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
EA202090817A1 (en) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US20200370012A1 (en) 2017-10-25 2020-11-26 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
JP7301047B2 (en) 2017-11-11 2023-06-30 ユニヴェルシテ・ドゥ・ストラスブール Compositions and methods for treating X-linked central nuclear myopathy
BR112020009136A2 (en) 2017-11-14 2020-10-13 Arcellx, Inc. polypeptides that contain domain and uses thereof
CA3082410A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
TW201922774A (en) 2017-11-15 2019-06-16 瑞士商諾華公司 BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
TW201925782A (en) 2017-11-30 2019-07-01 瑞士商諾華公司 BCMA-targeting chimeric antigen receptor, and uses thereof
CA3083236A1 (en) 2017-12-05 2019-06-13 Lonza Ltd Methods of assaying tropolone
JP7372920B2 (en) 2017-12-29 2023-11-01 セレクティス Methods for improving the generation of CAR T cells
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3645720B1 (en) 2018-02-02 2021-03-10 Lonza Ltd Methods of cell selection and modifying cell metabolism
AU2019217207A1 (en) 2018-02-12 2020-08-27 Diabetes-Free, Inc. Improved antagonistic anti-human CD40 monoclonal antibodies
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
AU2019235033A1 (en) 2018-03-14 2020-07-30 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
CN110372796B (en) 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 Chimeric antigen receptor targeting BCMA and preparation method and application thereof
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788064A1 (en) 2018-04-30 2021-03-10 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019217512A1 (en) 2018-05-08 2019-11-14 Life Technologies Corporation Compositions and methods for culturing and expanding cells
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201810181D0 (en) 2018-06-21 2018-08-08 Immetacyte Ltd Cells expressing chimeric recominant growth factor receptors
EP3833446A2 (en) 2018-08-10 2021-06-16 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
AU2019327569A1 (en) 2018-08-30 2021-04-29 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN112639083A (en) 2018-08-31 2021-04-09 诺华股份有限公司 Method for producing cells expressing chimeric antigen receptor
CN112912105A (en) 2018-08-31 2021-06-04 因维克蒂斯股份有限公司 Chimeric antigen receptors against multiple HLA-G isoforms
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
AU2019362029A1 (en) 2018-10-19 2021-04-01 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
MX2021004602A (en) 2018-10-22 2021-09-08 Univ Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein.
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
HRP20221200T1 (en) 2018-11-16 2022-12-09 Celgene Corporation Improved t cell manufacturing process
SG11202105010UA (en) 2018-11-16 2021-06-29 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
WO2020140007A1 (en) 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
US20220090088A1 (en) 2019-01-14 2022-03-24 University Of Rochester Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
CN113727720A (en) 2019-02-08 2021-11-30 生物技术细胞和基因治疗公司 Chimeric antigen receptor modified cells for the treatment of CLDN6 expressing cancers
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
RU2742000C2 (en) 2019-03-13 2021-02-01 Общество С Ограниченной Ответственностью "Анабион" Isolated alternative intracellular signalling domain of chimeric antigen receptor and chimeric antigen receptor including it
KR20230146132A (en) 2019-03-15 2023-10-18 카티전 테라퓨틱스, 인코포레이티드 Anti-bcma chimeric antigen receptors
CN114007635A (en) 2019-03-20 2022-02-01 法国国家科学研究中心 Dual-carrier protein/BIN 1 for treating autosomal dominant centronuclear myopathy
US11090336B2 (en) 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3967329A4 (en) 2019-05-07 2023-06-14 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
EP3994253A1 (en) 2019-07-02 2022-05-11 M6P Therapeutics (Switzerland) LLC Vector compositions and methods of using same for treatment of lysosomal storage disorders
WO2021016453A1 (en) 2019-07-23 2021-01-28 University Of Rochester Targeted rna cleavage with crispr-cas
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CN112300997A (en) 2019-08-01 2021-02-02 上海赛比曼生物科技有限公司 Universal CAR-T cell and preparation and application thereof
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
AU2020334237A1 (en) 2019-08-19 2022-02-10 Universität Basel Cell therapy methods
JP2022544825A (en) 2019-08-20 2022-10-21 プレシジョン バイオサイエンシズ，インク． Lymphocyte-depleting administration regimens for cellular immunotherapy
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
EP4058583A1 (en) 2019-11-14 2022-09-21 Lonza Ltd. Methods of cell selection
CN115925976A (en) 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 CD7-CAR-T cell and preparation and application thereof
MX2022006365A (en) 2019-11-26 2022-06-22 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof.
BR112022010206A2 (en) 2019-11-26 2022-11-29 Novartis Ag CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
AU2020401315B2 (en) 2019-12-11 2023-11-09 A2 Biotherapeutics, Inc. LILRB1-based chimeric antigen receptor
CA3168903A1 (en) 2020-02-07 2021-08-12 University Of Rochester Ribozyme-mediated rna assembly and expression
WO2021158982A2 (en) 2020-02-07 2021-08-12 University Of Rochester Targeted translation of rna with crispr-cas13 to enhance protein synthesis
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230174933A1 (en) 2020-02-27 2023-06-08 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (en) 2020-02-27 2022-10-11 诺华股份有限公司 Method for producing cells expressing chimeric antigen receptor
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
AU2021225920A1 (en) 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
EP4121115A1 (en) 2020-03-19 2023-01-25 Trizell Ltd. Temperature-responsive virus storage system
IL296546A (en) 2020-03-20 2022-11-01 Inst Nat Sante Rech Med Chimeric antigen receptor specific for human cd45rc and uses thereof
JP2023519307A (en) 2020-03-27 2023-05-10 ユニバーシティ オブ ロチェスター Targeted destruction of viral RNA by CRISPR-CAS13
US20230103771A1 (en) 2020-03-27 2023-04-06 University Of Rochester CRISPR-Cas13 crRNA Arrays
CN113527507A (en) 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 Chimeric antigen receptor targeting CD22 and preparation method and application thereof
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
US20230220057A1 (en) 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021252635A1 (en) 2020-06-11 2021-12-16 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers
JP2023534464A (en) 2020-07-15 2023-08-09 ユニバーシティ オブ ロチェスター Cleavage of target RNA by dCas13-RNase fusion protein
EP4183872A1 (en) 2020-07-16 2023-05-24 Shanghai Jiaotong University Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
AU2021308702A1 (en) 2020-07-17 2023-03-16 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US20230277670A1 (en) 2020-07-17 2023-09-07 John Bridgeman Chimeric molecules providing targeted costimulation for adoptive cell therapy
US20230330227A1 (en) 2020-08-13 2023-10-19 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
EP4058474A1 (en) 2020-08-20 2022-09-21 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
JP2023538115A (en) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Compositions and methods for treating CEACAM-positive cancers
JP2023538114A (en) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Compositions and methods for treating mesothelin-positive cancer
WO2022079308A1 (en) 2020-10-16 2022-04-21 Institut Pasteur Chimeric constructs useful in vaccination and cancer therapy
US20240033358A1 (en) 2020-11-13 2024-02-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
CN114525306A (en) 2020-11-23 2022-05-24 博生吉医药科技(苏州)有限公司 Preparation method and application of CD7-CAR-T cell
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
CN114763381A (en) 2021-01-13 2022-07-19 博生吉医药科技(苏州)有限公司 B7-H3 chimeric antigen receptor modified T cell and application thereof
CA3204730A1 (en) 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
CN114907485A (en) 2021-02-08 2022-08-16 浙江大学 Chimeric antigen receptor with endogenous protein molecule replacing single domain antibody
CN117597358A (en) 2021-02-16 2024-02-23 A2生物治疗股份有限公司 Compositions and methods for treating HER2 positive cancers
WO2022226296A2 (en) 2021-04-23 2022-10-27 University Of Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
TW202307210A (en) 2021-06-01 2023-02-16 瑞士商諾華公司 Cd19 and cd22 chimeric antigen receptors and uses thereof
CN115477704B (en) 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on LOX1
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
CN115477705B (en) 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on granzyme B
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202317633A (en) 2021-07-08 2023-05-01 美商舒泰神（加州）生物科技有限公司 Antibodies specifically recognizing tnfr2 and uses thereof
CN115812082A (en) 2021-07-14 2023-03-17 舒泰神（北京）生物制药股份有限公司 Antibody specifically recognizing CD40 and application thereof
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
US20230277600A1 (en) 2021-10-20 2023-09-07 University Of Rochester Treatment Of Age-Related White Matter Loss By Competitive Replacement Of Glial Cells
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2023105005A1 (en) 2021-12-09 2023-06-15 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2023177954A1 (en) 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
WO2023215860A1 (en) 2022-05-05 2023-11-09 University Of Rochester Modified bacteria and methods of use for bioglass microlenses
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139413T1 (en) * 1991-03-26 1996-07-15 Mogen Int METHOD FOR ISOLATION AND/OR SAMPLING GENES AND PROMOTORS RELATED TO PLANT-NEMATOD INTERACTIONS USING PLANTS OF THE SEX ARABIDOPSIS
AU2928492A (en) * 1991-11-20 1993-06-15 Mogen International N.V. A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2001037654A2 (en) * 1999-11-24 2001-05-31 Dna Plant Technology Corporation METHOD OF EXPRESSING dsRNA IN PLANTS TO INHIBIT INSECT PESTS

Also Published As

Publication number Publication date
WO2001096584A2 (en) 2001-12-20
WO2001096584A3 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
AU2001275474A1 (en) Materials and methods for the control of nematodes
AU2001234473A1 (en) Stabilized silica and methods of making and using the same
AU2001266583A1 (en) Epothilone derivatives and methods for making and using the same
AU2002213831A1 (en) Actuating member and method for producing the same
AU2001269847A1 (en) Lateral displacement pier and method of installing the same
AU2002367483A1 (en) Materials and methods for controlling pests
AU2001267079A1 (en) Integrated electronic-optoelectronic devices and method of making the same
AU5454500A (en) Magnetically enhanced composite materials and methods for making and using the same
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2001257075A1 (en) Screen and method of making the same
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2000273206A1 (en) Photocatalyst-bearing material and method of producing the same
AU7698500A (en) Microfluidic structures and methods of fabrication
AU2001245288A1 (en) Overhanging form system and method of using the same
AU2001275007A1 (en) Methods of testing materials
AU2001279535A1 (en) Bone-regeneration material
AU2001239773A1 (en) Baroplastic materials
AU2001260774A1 (en) Bio-support and preparing method of the same
AU2001234500A1 (en) Materials and methods for biological control of soilborne pathogens
AU2002228801A1 (en) Post-crepe stabilized material and method of producing the same
AU2001291288A1 (en) Webpad and method for using the same
AU2001278951A1 (en) Compounds and methods
AU2001262228A1 (en) Stabilized steroidal suspension
AU2001290375A1 (en) Impactor control
AU2000244990A1 (en) Footwear structure and method of forming the same